230 related articles for article (PubMed ID: 38258034)
1. Phosphodiesterase-4 Inhibition in the Management of Psoriasis.
Crowley EL; Gooderham MJ
Pharmaceutics; 2023 Dec; 16(1):. PubMed ID: 38258034
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase-4 Inhibition in Psoriasis.
Milakovic M; Gooderham MJ
Psoriasis (Auckl); 2021; 11():21-29. PubMed ID: 33763335
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases.
Li H; Zuo J; Tang W
Front Pharmacol; 2018; 9():1048. PubMed ID: 30386231
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.
Bhat A; Ray B; Mahalakshmi AM; Tuladhar S; Nandakumar DN; Srinivasan M; Essa MM; Chidambaram SB; Guillemin GJ; Sakharkar MK
Pharmacol Res; 2020 Oct; 160():105078. PubMed ID: 32673703
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.
Wittmann M; Helliwell PS
Dermatol Ther (Heidelb); 2013 Jun; 3(1):1-15. PubMed ID: 23888251
[TBL] [Abstract][Full Text] [Related]
6. Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.
Jarnagin K; Chanda S; Coronado D; Ciaravino V; Zane LT; Guttman-Yassky E; Lebwohl MG
J Drugs Dermatol; 2016 Apr; 15(4):390-6. PubMed ID: 27050693
[TBL] [Abstract][Full Text] [Related]
7. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
Gooderham M; Papp K
BioDrugs; 2015 Oct; 29(5):327-39. PubMed ID: 26481941
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase 4 inhibitors.
Zebda R; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S43-S52. PubMed ID: 29248522
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.
Sakkas LI; Mavropoulos A; Bogdanos DP
Curr Med Chem; 2017; 24(28):3054-3067. PubMed ID: 28554321
[TBL] [Abstract][Full Text] [Related]
10. Treatment of psoriasis with crisaborole.
Lee EB; Lebwohl MG; Wu JJ
J Dermatolog Treat; 2019 Mar; 30(2):156-157. PubMed ID: 29812961
[TBL] [Abstract][Full Text] [Related]
11. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
Schafer P
Biochem Pharmacol; 2012 Jun; 83(12):1583-90. PubMed ID: 22257911
[TBL] [Abstract][Full Text] [Related]
12. Crisaborole efficacy in murine models of skin inflammation and Staphylococcus aureus infection.
Youn C; Dikeman DA; Chang E; Liu H; Nolan SJ; Alphonse MP; Joyce DP; Liu Q; Meixiong J; Dong X; Miller LS; Archer NK
Exp Dermatol; 2023 Apr; 32(4):425-435. PubMed ID: 36461082
[TBL] [Abstract][Full Text] [Related]
13. PDE4 inhibitors: potential protective effects in inflammation and vascular diseases.
Fan T; Wang W; Wang Y; Zeng M; Liu Y; Zhu S; Yang L
Front Pharmacol; 2024; 15():1407871. PubMed ID: 38915460
[TBL] [Abstract][Full Text] [Related]
14. Apremilast for the treatment of psoriasis.
Chimenti MS; Gramiccia T; Saraceno R; Bianchi L; Garofalo V; Buonomo O; Perricone R; Chimenti S; Chiricozzi A
Expert Opin Pharmacother; 2015; 16(13):2083-94. PubMed ID: 26243735
[TBL] [Abstract][Full Text] [Related]
15. Advances in the development of phosphodiesterase-4 inhibitors.
Li G; He D; Cai X; Guan W; Zhang Y; Wu JQ; Yao H
Eur J Med Chem; 2023 Mar; 250():115195. PubMed ID: 36809706
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase 4 inhibitors in diabetic nephropathy.
Ookawara M; Nio Y
Cell Signal; 2022 Feb; 90():110185. PubMed ID: 34785349
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.
Schafer PH; Truzzi F; Parton A; Wu L; Kosek J; Zhang LH; Horan G; Saltari A; Quadri M; Lotti R; Marconi A; Pincelli C
Cell Signal; 2016 Jul; 28(7):753-63. PubMed ID: 26806620
[TBL] [Abstract][Full Text] [Related]
18. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis.
Bäumer W; Hoppmann J; Rundfeldt C; Kietzmann M
Inflamm Allergy Drug Targets; 2007 Mar; 6(1):17-26. PubMed ID: 17352685
[TBL] [Abstract][Full Text] [Related]
19. ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study.
Kubota-Ishida N; Kaji C; Matsumoto S; Wakabayashi T; Matsuhira T; Okura I; Cho N; Isshiki S; Kumura K; Tabata Y
Eur J Pharmacol; 2024 Jan; 962():176202. PubMed ID: 37996010
[TBL] [Abstract][Full Text] [Related]
20. Characterization of LY2775240, a selective phosphodiesterase-4 inhibitor, in nonclinical models and in healthy subjects.
Patel DR; Urva S; Ho S; Buckman CJ; Ma Y; Lim J; Sissons SE; Zuniga MS; Philips D; Cox K; Dairaghi DJ
Clin Transl Sci; 2021 May; 14(3):1037-1048. PubMed ID: 33382916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
